Article Information
History
- January 28, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- CAS Key Laboratory of Receptor Research; Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China
- ↵*To whom correspondence should be addressed. Phone: +86-21-50806600-1201 (Z.X.), +86-21-50805020 (W.Z.), E-mail: zjxu{at}simm.ac.cn (Z.X.), wlzhu{at}simm.ac.cn (W.Z.).
Posted January 28, 2020.
Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation
